Clinical Trial SuccessCelldex has two pivotal Phase III trials ongoing for barzolvolimab in chronic spontaneous urticaria, with a high likelihood of clinical success based on Phase II results.
Revenue OpportunityImpressive Phase II data in chronic inducible urticaria led to an upcoming Phase III program, presenting a significant revenue opportunity.
Safety ProfileBarzolvolimab's safety and tolerability profile was clean with no anaphylaxis, no hypersensitivity, and no treatment-related serious adverse events.